Ben Warrick

We make expert medical knowledge easy to access, so clinicians can offer the best treatment for their patients.

[Kate Sears @MedwatchKate]

Hi friends, it's #Prostate Cancer Friday! Here are Top Posts of the Week 🧵

1/ @neerajaiims on the FDA approval of capivasertib for mHSPC/APMS prostate cancer:
https://t.co/ko0gAhKiPR

[Karina Verma @karinapverma]

Today I learned about @OpenMedicineHQ and their endeavors in building user friendly algorithms to aid with oncology care and treatment decisions. @allisonoconn @grace_ferri.

[Kate Sears @MedwatchKate]

Hi friends, it's #AcuteMyeloidLeukemia Thursday! #EHA2026 edition 🎉🎉🎉

Here are Top Posts of the Week 🧵

1/ @sanamloghavi @lindemilesphd and @AkEisfeld on BRAF mutations in AML:
https://t.co/tIGMtyKvVj

[Open Medicine @OpenMedicineHQ]

First-line Advanced/Metastatic Squamous NSCLC: HARMONi-6 based Treatment Selection from @BenBleibergMD @CharuAggarwalMD: https://t.co/biPKjtYLdI

[Kate Sears @MedwatchKate]

Hi friends, it's #LungCancer Wednesday! Here are Top Posts of the Week 🧵

1/ @StephenVLiu on an analysis of patients receiving IO for NSCLC:
https://t.co/t63DsHtZQD

[Open Medicine @OpenMedicineHQ]

Management of 1st Relapse Multiple Myeloma from @rajshekharucms: https://t.co/Yb50UONOYJ

[Kate Sears @MedwatchKate]

Hi friends, it's #BreastCancer Tuesday! Here are Top Posts of the Week 🧵

1/ @dr_yakupergun with a case on metastatic HR−/HER2+ breast cancer:
https://t.co/nNgkuq3Qpx

[Kate Sears @MedwatchKate]

Announcing the Top Posts of #EHA2026! 🎉🎉🎉

1/ @VincentRK on Monumental-3 in relapsed myeloma:
https://t.co/YY9HXlT6Qo

[Kate Sears @MedwatchKate]

Hi friends, it's #ProstateCancer Friday! Here are Top Posts of the Week 🧵

1/ @OncoAlert on integrating ARPIs into practice:
https://t.co/YdzC4jD3Yu

[Kate Sears @MedwatchKate]

Hi friends, it's #AcuteMyeloidLeukemia Thursday! #EHA2026 edition 🎉🎉🎉

Here are Top Posts of the Week 🧵

1/ @Dr_AmerZeidan on a decade of progress in treating AML:
https://t.co/1cSjyVXBz2

[Kate Sears @MedwatchKate]

Hi friends, it's #LungCancer Wednesday! Here are Top Posts of the Week 🧵

1/ @jennifermarksmd on neoadjuvant lorlatinib in stage 2 ALK+ NSCLC: https://t.co/pEIRWGo5Lm

[Open Medicine @OpenMedicineHQ]

Newly Diagnosed Myeloma from @VincentRK: https://t.co/3GnbnIe4P1

[Kate Sears @MedwatchKate]

Hi friends, it's #BreastCancer Tuesday! Here are Top Posts of the Week 🧵

1/ @DrHBurstein and @dr_yakupergun on the most important discussion at #ASCO26:
https://t.co/oB1EVuo3Gl

[Open Medicine @OpenMedicineHQ]

STK11/KEAP1 Advanced/Metastatic Squamous NSCLC from @CharuAggarwalMD @BenBleibergMD: https://t.co/3dbPVlUa6H

[Kate Sears @MedwatchKate]

Hi friends, it's #Myeloma Monday! Here are Top Posts of the Week 🧵

1/ @VincentRK on bispecifics in first relapse:
https://t.co/JgZhBjitbz

[Open Medicine Insights @OpenMedInsights]

#ASCO26 through an algorithm lens
@ASCO
LIBRETTO-432 / LBA3
Primary publication in NEJM:
https://t.co/epek0iUjjv
Clinical decision point:
In early-stage NSCLC, should comprehensive molecular testing at diagnosis guide adjuvant targeted therapy after definitive local treatment?

LIBRETTO-432 tested adjuvant selpercatinib vs placebo in early-stage RET fusion–positive NSCLC after definitive therapy.

Key data:

• global phase III randomized trial
• 151 patients with stage IB–IIIA RET fusion–positive NSCLC
• selpercatinib for up to 3 years
• primary efficacy population: stage II–IIIA
• median EFS: not reached vs 31.8 months
• 2-year EFS: 91.5% vs 61.1%
• EFS HR: 0.172
• OS immature
@lungoncdoc @StephenVLiu @GlopesMd @ADesaiMD @M_Torasawa @Tony_Calles
Potential algorithm impact:

LIBRETTO-432 changes the early-stage NSCLC algorithm at the testing node.
The key step is not only:
“Which adjuvant treatment?”
It is:
“Was molecular testing done early enough to identify the adjuvant option?”
A future pathway should include:
Diagnose potentially curable NSCLC
Stage accurately

Preserve tissue for comprehensive molecular testing

Test for actionable drivers, including RET fusions

Complete surgery or definitive radiation ± systemic therapy when indicated

If RET fusion-positive and eligible: consider adjuvant selpercatinib

Monitor liver enzymes, blood pressure, diarrhea, dry mouth, QT/drug interactions and adherence

Continue surveillance and long-term follow-up

Bottom line:

LIBRETTO-432 is not only an adjuvant RET-inhibitor trial.
It is an early-stage molecular-testing trial in practice.

[Kate Sears @MedwatchKate]

Hi friends, it's #ProstateCancer Friday! Here are Top Posts of the Week 🧵

1/ @montypal celebrates @neerajaiims for TALAPRO-3:
https://t.co/PafMN9tlaf

[Simon C @scserendipity1]

There is also a gap in innovation and adoption.

From approval to the patients takes too long

@OpenMedInsights we are trying to change this. Great algorithm from @MPishvaian @drallysonocean @GIMedOnc and the Open Medicine team..

@EileenMOReilly @RevMedicines @YJanjigianMD

https://t.co/5UcdtEisVf

[Mark Lewis, MD, FASCO @marklewismd]

One of the most transformative conferences I’ve ever attended — the best part was bringing legitimate hope back to patients in clinic this week

[Open Medicine @OpenMedicineHQ]

Advanced Dedifferentiated Liposarcoma: Systemic Therapy from @wagsmd: https://t.co/G8KQVAt1fe